EUVIMEDEUVIMED entdecken
Übersichtsarbeit

RNA therapeutics for epilepsy: An emerging modality for drug discovery

Stine N Hansen iD, Anja Holm iD, Sakari Kauppinen iD, Henrik Klitgaard iD

Epilepsia · 2023-12 · 64 (12) · 3113-3129

DOI: 10.1111/epi.17772 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Epilepsia, online erschienen am 10.10.2023. Verfasst von Stine N Hansen und 3 weiteren Autor:innen. Beteiligte Einrichtung: NEUmiRNA Therapeutics, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Epilepsy, MicroRNAs, Drug Resistant Epilepsy. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 107 Literaturangaben. Gefördert von: Innovationsfonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug discovery in epilepsy began with the finding of potassium bromide by Sir Charles Locock in 1857. The following century witnessed the introduction of phenotypic screening tests for discovering antiseizure medications (ASMs). Despite the high success rate of developing ASMs, they have so far failed in eliminating drug resistance and in delivering disease‐modifying treatments. This emphasizes the need for new drug discovery strategies in epilepsy. RNA‐based drugs have recently shown promise as a new modality with the potential of providing disease modification and counteracting drug resistance in epilepsy. RNA therapeutics can be directed either toward noncoding RNAs, such as microRNAs, long noncoding RNAs (ncRNAs), and circular RNAs, or toward messenger RNAs. The former show promise in sporadic, nongenetic epilepsies, as interference with ncRNAs allows for modulation of entire disease pathways, whereas the latter seem more promising in monogenic childhood epilepsies. Here, we describe therapeutic strategies for modulating disease‐associated RNA molecules and highlight the potential of RNA therapeutics for the treatment of different patient populations such as sporadic, drug‐resistant epilepsy, and childhood monogenic epilepsies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EpilepsyMicroRNAsDrug Resistant EpilepsyHumansChildDrug DiscoveryDrug Resistance

Stichwörter der Autor:innen

ASORNA medicineseizuressiRNA

Substanzen

MicroRNAs

Autor:innen und Institutionen

  • NEUmiRNA Therapeutics, Copenhagen, Denmark.
  • Department of Clinical Medicine, Center for RNA Medicine, Aalborg University, Copenhagen, Denmark.

ORCID-Profile: Stine N Hansen, Anja Holm, Sakari Kauppinen, Henrik Klitgaard

Förderung

  • Innovationsfonden

Zitieren

APA

Hansen, S. N., Holm, A., Kauppinen, S., & Klitgaard, H. (2023). RNA therapeutics for epilepsy: An emerging modality for drug discovery. Epilepsia, 64(12), 3113-3129. https://doi.org/10.1111/epi.17772

Vancouver

Hansen SN, Holm A, Kauppinen S, Klitgaard H. RNA therapeutics for epilepsy: An emerging modality for drug discovery. Epilepsia. 2023;64(12):3113-3129. doi:10.1111/epi.17772

BibTeX
@article{Hansen2023,
  author = {Hansen, Stine N and Holm, Anja and Kauppinen, Sakari and Klitgaard, Henrik},
  title = {RNA therapeutics for epilepsy: An emerging modality for drug discovery},
  journal = {Epilepsia},
  year = {2023},
  volume = {64},
  number = {12},
  pages = {3113--3129},
  doi = {10.1111/epi.17772}
}
Kostenlos starten →